@NathanSinghLab
Account based inBelize
About this account
- Account based in
- Belize
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
Using immunology, genomics and structural biology to engineer smarter cellular immunotherapies for cancer.
St Louis, MO
Joined April 2019
- Tweets293
- Following453
- Followers1K
- Likes931
Pinned Tweet
Returning to Twitter (brielfy) to share publication of our article "BACH2 regulates T cell lineage state to enhance CAR T cell function" today in Nature Immunology! rdcu.be/eZlwj
1 of 3 studies (!) (others led by @RoychoudhuriLab and Tuoqi Wu) published together that...
Nathan Singh retweeted
The paper is part of three parallel submissions from @NathanSinghLab & Tuoqi Wu arriving at similar conclusions - that the dosage of BACH2 and the timing of its induction are key to enhancing #celltherapy for cancer. @Cambridge_Uni @CRUKCambridge
identify the central role of BACH2 in T cell lineage decisions and function. A real pleasure working with the NI team and these great investigators! A great example complementary instead of competitive work strengthening the observation!
Cell Therapy Keystone 2025 is coming! If you're interested in cell engineering, immunotherapy, cancer or autoimmunity (!) this meeting is for you! Join us in Banff for a fantastic symposium this March. Abstract deadline 12/9! @lab_rezvani
keystonesymposia.org/confere…
Nathan Singh retweeted
There is no cavalry coming. No miracle solution. No saviors.
In the end, we, the American people-not any of our institutions-have to save our democracy by registering and voting in defense of our freedoms the next two months.
We are the cavalry. The responsibility is ours.
Checkout our paired Perspective and Priority Brief in @CIR_AACR! Amazing collab with @carlhjune, @JoeFraietta and @GillSaar that we hope will help researchers, product developers and regulators advance gene edited T cell therapies.
aacrjournals.org/cancerimmun…
Incredibly creative work highlighting the broad applications of T cell immunotherapy - congrats Jony and team!
Excited to share a new work from @kipnislab by amazing Wenqing Gao (twitter-less) on developing engineered T cell therapy for CNS injury || nature.com/articles/s41586-0…
Looking for a small meeting with leaders in cell therapy discussing high impact translational research? Look no further! The UChicago Jonas Center Symposium is for you! Please get in touch if you're interested or, better yet, register and join us!
cme.uchicago.edu/JCCTS2024
Nathan Singh retweeted
NEW - Regulatory Considerations for Genome-Edited T-cell Therapies, on navigating complexities in bringing new technologies to regulatory submissions, clinical trials. From @NathanSinghLab & colleagues @PennMedicine @CIR_AACR #geneediting #CRISPR aacrjournals.org/cancerimmun…
Nathan Singh retweeted
Now online in @CD_AACR: Rational Protein Engineering to Enhance MHC-independent T Cell Receptors - by Ju-Fang Chang, @NathanSinghLab, and colleagues doi.org/10.1158/2159-8290.CD… @WUSTLmed
Are all hybrid antigen receptors as easy to design as CARs? Definitely not! doi.org/10.1158/2159-8290.CD… (1/4)
Using advanced modeling tools, we alleviated these conflicts to enhance receptor function across a variety of tumor models. A clear demonstration that design of synthetic immunotherapies requires consideration of de novo protein structures. (3/4)
Huge shout out to Twitter-less Ju-fang Chang, our structural biologist extraordinaire who drove this work from start to finish, and the amazing editorial team @CancerDiscovery. (4/4)
Looking for the most effective ways to CRISPR edit human T cells? Look no further! Along with the team @Penn we identified the engineering steps that control product function. Nearly 10 years of troubleshooting with Cas9 and novel base editors distilled down into 4 figures! (1/4)
Huge shout out to @JoeFraietta, @carlhjune, Gerry Linette, Saar Gill and the team @CIR_AACR – a great experience collaborating with colleagues and editors to get these findings out to the community.